Adverum Biotechnologies Book Value 2011-2026 | ADVM

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Adverum Biotechnologies

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
70.7 M	67.2 M	182 M	316 M	434 M	175 M	201 M	184 M	216 M	253 M	149 M	-218 K	-997 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
434 M	-997 K	173 M

Quarterly Book Value Adverum Biotechnologies

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-55.7 M	-20.2 M	26.4 M	144 M	168 M	182 M	103 M	131 M	158 M	182 M	208 M	244 M	283 M	316 M	346 M	379 M	415 M	434 M	434 M	434 M	434 M	175 M	175 M	175 M	175 M	201 M	201 M	201 M	201 M	184 M	184 M	184 M	184 M	216 M	216 M	216 M	216 M	253 M	253 M	253 M	253 M	149 M	149 M	149 M	149 M	-218 K	-218 K	-218 K	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
434 M	-55.7 M	201 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
Assembly Biosciences ASMB	207 M	$ 28.46	3.45 %	$ 319 M	USA
Ascendis Pharma A/S ASND	-163 M	$ 221.88	-0.87 %	$ 5 B	Danmark
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Axsome Therapeutics AXSM	88.3 M	$ 156.92	-1.23 %	$ 7.81 B	USA
Galera Therapeutics GRTX	6.55 M	-	-32.59 %	$ 7.61 M	USA
Pharming Group N.V. PHAR	-191 M	$ 15.36	-0.71 %	$ 7.59 B	Niderland
Autolus Therapeutics plc AUTL	427 M	$ 1.37	-4.2 %	$ 350 M	Britain
Kamada Ltd. KMDA	319 M	$ 8.5	-1.39 %	$ 260 M	Israel
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
Benitec Biopharma BNTC	97.3 M	$ 10.98	-4.52 %	$ 452 M	USA
Inventiva S.A. IVA	-107 M	$ 5.78	-4.3 %	$ 138 M	France
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Compugen Ltd. CGEN	132 M	$ 2.09	-0.95 %	$ 195 M	Israel
Tiziana Life Sciences PLC TLSA	3.94 M	$ 1.21	-3.97 %	$ 71.5 M	Britain
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
PainReform Ltd. PRFX	1.82 M	$ 2.28	-0.44 %	$ 1.03 M	Israel
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Foghorn Therapeutics FHTX	-108 M	$ 5.0	2.25 %	$ 315 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
AbCellera Biologics ABCL	967 M	$ 3.4	-3.68 %	$ 1.02 B	Canada
BioMarin Pharmaceutical BMRN	6.09 B	$ 54.13	-1.64 %	$ 10.4 B	USA
Curis CRIS	-6 M	$ 0.77	1.89 %	$ 4.86 M	USA
Bellerophon Therapeutics BLPH	2.53 M	-	-74.18 %	$ 955 K	USA
AgeX Therapeutics AGE	5.36 M	-	-10.17 %	$ 12.2 K	USA
Coherus BioSciences CHRS	61 M	$ 1.52	-5.59 %	$ 178 M	USA
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Burford Capital Limited BUR	1.66 B	$ 7.7	-5.87 %	$ 1.29 B	Britain
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Cellectis S.A. CLLS	75.9 M	$ 3.34	-4.02 %	$ 116 M	France
Arbutus Biopharma Corporation ABUS	106 M	$ 4.24	-2.97 %	$ 704 M	Canada
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	176 M	-	-0.23 %	$ 916 M	USA
AIkido Pharma AIKI	39.9 M	-	1.93 %	$ 17.4 M	USA
Cardiff Oncology CRDF	45.4 M	$ 1.8	-1.1 %	$ 120 M	USA
Allakos ALLK	169 M	-	-	$ 28.6 M	USA
Cabaletta Bio CABA	236 M	$ 2.94	-3.29 %	$ 3.43 M	USA
Iterum Therapeutics ITRM	-4.08 M	$ 0.16	-5.45 %	$ 3.15 M	Irlanda
Brickell Biotech BBI	11.6 M	-	-5.38 %	$ 6.06 M	USA
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA